N/A
Completed N=106
A Novel Device for the Management of ADHD
Source: ClinicalTrials.gov NCT05777785 ↗Enrolled (actual)
106
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up — 39.76; 38.27 score on a scale
Summary
This is a 2-months study, where eligible ADHD adult participants will be provided with personalized VIZO glasses.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up |
39.76; 38.27 | — |
| PRIMARY Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up |
21.20; 20.22 | 0.037 sig |
| SECONDARY Clinical Global Impression-Improvement (CGI-I) - Rate at 2 Months Follow up |
77; 11 | — |
| SECONDARY Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up |
50.03; 47.95 | 0.027 sig |
| SECONDARY Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) - Metacognitive Index - at Baseline and 2 Months Follow up |
79.85; 77.76 | 0.029 sig |
Eligibility Criteria
Inclusion Criteria
- Documented history of primary ADHD diagnosis by certified clinicians
- Age 18-40 y
- Written informed consent
- Able and willing to complete all required ratings and assessments
Exclusion criteria
- Any current psychiatric / neurological comorbidity (e.g., epilepsy, Autism, depression, TBI, etc), other than ADHD
- ADHD Medications (stimulants, non-stimulants, other)
- Neurofeedback, cognitive training
Data sourced from ClinicalTrials.gov (NCT05777785). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.